Scanning electron micrograph of a cluster of Acinetobacter baumannii bacteria.

New antibiotics need AI that gets resistance right

Recursion Pharmaceuticals Logo

Recursion’s Phase 3 FAP trial will count large-polyp removals as events under FDA-agreed design

Ball-and-stick model of the cancer drug imatinib

After six years in stealth, Humanitas bets on hybrid AI for drug discovery

NIH is reorganizing clinical trial funding by trial type instead of disease

Unlocking PROTAC potential through better delivery

Chemical formula of psilocybin

Psychedelic pioneer Compass files for FDA approval as rivals close in

FDA’s GLP-1 vision warning rests on mixed evidence

Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027

Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3